Compare Citius Pharmaceuticals Inc (CTXR) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Mattel Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Mattel Inc trades at $13.49 (market cap $3.97B). The key difference: Mattel Inc is far larger — about 271.2× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | MAT | |
|---|---|---|
Market Cap | $14.64M | $3.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $22.16 |
52-Week Low | $0.53 | $13.05 |
Enterprise Value | $10.86M | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Mattel (MAT) trades at $13.84, up 3.83% today, with a bullish technical signal and strong valuation metrics including a P/E of 8.86 and P/S of 0.81. Recent earnings showed a Q1 2026 beat but Q3-Q4 2025 misses, while revenue stability around $5.4B supports a 9.27% net margin. News highlights include Comic-Con exclusives and a Barbie-Dunkin' collaboration, though cash flow turned negative in 2025.
The stock presents value with low multiples and 50% analyst buy ratings, targeting $14.60 consensus. Risks include volatile earnings, debt load, and activist pressure for a sale. Upside depends on brand execution offsetting consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
